Related references
Note: Only part of the references are listed.VEGFR2 blockade augments the effects of tyrosine kinase inhibitors by inhibiting angiogenesis and oncogenic signaling in oncogene-driven non-small-cell lung cancers
Hiromi Watanabe et al.
CANCER SCIENCE (2021)
Phase 1b Study of Sintilimab Plus Anlotinib as First-line Therapy in Patients With Advanced NSCLC
Tianqing Chu et al.
JOURNAL OF THORACIC ONCOLOGY (2021)
NSD2 promotes tumor angiogenesis through methylating and activating STAT3 protein
Da Song et al.
ONCOGENE (2021)
Anlotinib combined with gefitinib can significantly improve the proliferation of epidermal growth factor receptor-mutant advanced non-small cell lung cancer in vitro and in vivo
Tao Li et al.
TRANSLATIONAL LUNG CANCER RESEARCH (2021)
The combination of EGFR-TKIs and anlotinib as a first-line therapy for EGFR-mutant advanced non-small cell lung cancer: A multicenter, single-arm, phase II clinical trial.
Zhiyong He et al.
JOURNAL OF CLINICAL ONCOLOGY (2021)
A multicenter, randomized, double-blind study of gefitinib in combination with anlotinib or placebo in previously untreated patients with EGFR mutation-positive advanced non-small cell lung cancer (FL-ALTER).
Li Zhang et al.
JOURNAL OF CLINICAL ONCOLOGY (2021)
EGFR/Ras-induced CCL20 production modulates the tumour microenvironment
Andreas Hippe et al.
BRITISH JOURNAL OF CANCER (2020)
Longitudinal therapy monitoring of ALK-positive lung cancer by combined copy number and targeted mutation profiling of cell-free DNA
Steffen Dietz et al.
EBIOMEDICINE (2020)
CCL15 Recruits Suppressive Monocytes to Facilitate Immune Escape and Disease Progression in Hepatocellular Carcinoma
Long-Zi Liu et al.
HEPATOLOGY (2019)
Autophagy inhibition potentiates the anti-angiogenic property of multikinase inhibitor anlotinib through JAK2/STAT3/VEGFA signaling in non-small cell lung cancer cells
Lijun Liang et al.
JOURNAL OF EXPERIMENTAL & CLINICAL CANCER RESEARCH (2019)
Erlotinib plus bevacizumab versus erlotinib alone in patients with EGFR-positive advanced non-squamous non-small-cell lung cancer (NEJ026): interim analysis of an open-label, randomised, multicentre, phase 3 trial
Haruhiro Saito et al.
LANCET ONCOLOGY (2019)
Phase II Trial of the Combination of Alectinib with Bevacizumab in ALK-Positive Nonsquamous Non-Small Cell Lung Cancer
S. Watanabe et al.
JOURNAL OF THORACIC ONCOLOGY (2019)
CT-707 Overcomes Resistance of Crizotinib through Activating PDPK1-AKT1 Pathway by Targeting FAK
Caixia Liang et al.
CURRENT CANCER DRUG TARGETS (2019)
Role of anlotinib-induced CCL2 decrease in anti-angiogenesis and response prediction for nonsmall cell lung cancer therapy
Jun Lu et al.
EUROPEAN RESPIRATORY JOURNAL (2019)
Concomitant resistance mechanisms to multiple tyrosine kinase inhibitors in ALK-positive non-small cell lung cancer
Yongfeng Yu et al.
LUNG CANCER (2019)
Redundant angiogenic signaling and tumor drug resistance
Rajesh N. Gacche et al.
DRUG RESISTANCE UPDATES (2018)
Impact of EML4-ALK Variant on Resistance Mechanisms and Clinical Outcomes in ALK-Positive Lung Cancer
Jessica J. Lin et al.
JOURNAL OF CLINICAL ONCOLOGY (2018)
Response to crizotinib in advanced &ITALK&IT-rearranged non-small cell lung cancers with different &ITALK&IT-fusion variants
Yan Li et al.
LUNG CANCER (2018)
Anlotinib: a novel multi-targeting tyrosine kinase inhibitor in clinical development
Guoshuang Shen et al.
JOURNAL OF HEMATOLOGY & ONCOLOGY (2018)
Effect of Anlotinib as a Third-Line or Further Treatment on Overall Survival of Patients With Advanced Non-Small Cell Lung Cancer The ALTER 0303 Phase 3 Randomized Clinical Trial
Baohui Han et al.
JAMA ONCOLOGY (2018)
Differential protein stability and clinical responses of EML4-ALK fusion variants to various ALK inhibitors in advanced ALK-rearranged non-small cell lung cancer
C. G. Woo et al.
ANNALS OF ONCOLOGY (2017)
Further Advances in the Management of Anaplastic Lymphoma Kinase-Mutated Non-Small-Cell Lung Cancer
Sai-Hong Ignatius Ou
JOURNAL OF CLINICAL ONCOLOGY (2017)
Circulating Tumor Cells with Aberrant ALK Copy Number Predict Progression-Free Survival during Crizotinib Treatment in ALK-Rearranged Non-Small Cell Lung Cancer Patients
Emma Pailler et al.
CANCER RESEARCH (2017)
Differential Crizotinib Response Duration Among ALK Fusion Variants in ALK-Positive Non-Small-Cell Lung Cancer
Tatsuya Yoshida et al.
JOURNAL OF CLINICAL ONCOLOGY (2016)
Disruption of CCL20-CCR6 interaction inhibits metastasis of advanced cutaneous T-cell lymphoma
Sho Ikeda et al.
ONCOTARGET (2016)
Serum chemokine network correlates with chemotherapy in non-small cell lung cancer
Dawei Yang et al.
CANCER LETTERS (2015)
Tobacco smoke induces production of chemokine CCL20 to promote lung cancer
Gui-Zhen Wang et al.
CANCER LETTERS (2015)
BEYOND: A Randomized, Double-Blind, Placebo-Controlled, Multicenter, Phase III Study of First-Line Carboplatin/Paclitaxel Plus Bevacizumab or Placebo in Chinese Patients With Advanced or Recurrent Nonsquamous Non-Small-Cell Lung Cancer
Caicun Zhou et al.
JOURNAL OF CLINICAL ONCOLOGY (2015)
The pros and cons of chemokines in tumor immunology
Antonella Viola et al.
TRENDS IN IMMUNOLOGY (2012)
Hallmarks of Cancer: The Next Generation
Douglas Hanahan et al.
CELL (2011)
Tumor response to combination celecoxib and erlotinib therapy in non-small cell lung cancer is associated with a low baseline matrix metalloproteinase-9 and a decline in serum-soluble E-cadherin
Karen L. Reckamp et al.
JOURNAL OF THORACIC ONCOLOGY (2008)
Identification of the transforming EML4-ALK fusion gene in non-small-cell lung cancer
Manabu Soda et al.
NATURE (2007)
The chemokine network: A target in cancer biology?
Violet I. F. Slettenaar et al.
ADVANCED DRUG DELIVERY REVIEWS (2006)
Angiogenesis and lung cancer: Prognostic and therapeutic implications
RS Herbst et al.
JOURNAL OF CLINICAL ONCOLOGY (2005)
Share Paper
